Dave Hering, Invivyd CEO
January 3, 2024 07:13 AM EST
FDA+
Coronavirus

In­vivyd re­quests emer­gency use au­tho­riza­tion for Covid-19 pre­ven­tive an­ti­body among im­muno­com­pro­mised

Katherine Lewin

News Reporter

In­vivyd has asked the FDA for an emer­gency use au­tho­riza­tion for its Covid-19 pre-ex­po­sure pre­ven­tion an­ti­body, the Mass­a­chu­setts-based biotech an­nounced Wednes­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times